Drug Composition and Coating

According to the invention there is provided inter alia a medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent, when formulated in the coating layer, is stable to sterilization. 1. A medical device for delivering a therapeutic agent to a tissue , the device having a solid surfactant-free particulate coating layer applied to a surface of the device , the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent , when formulated in the coating layer , is stable to sterilization.2. A method for preparing a medical device according to claim 1 , which comprises the steps of combining the therapeutic agent and the at least one organic additive in powder form claim 1 , and then applying the powder to the device to form a solid particulate composition and optionally applying a subsequent thermal treatment step. The present invention relates to solid paclitaxel compositions, medical devices with coatings comprising solid paclitaxel compositions and to ...

IMPLANTABLE MEDICAL DEVICE

According to the invention there is provided inter alia an implantable medical device with coatings comprising an immobilized heparin moiety and elutable paclitaxel and to methods for making such devices. 1. An implantable medical device with a surface having a coating comprising:a first coating layer comprising an immobilized heparin moiety and a second particulate coating layer comprising elutable paclitaxel and at least one organic additive, wherein at least a portion of the second particulate coating layer is in contact with at least a portion of the first coating layer.2. An implantable medical device according to claim 1 , wherein the medical device is a tubular medical device.3. An implantable medical device according to claim 1 , wherein the first coating layer comprises a polymer.4. An implantable medical device according to claim 3 , wherein the heparin moiety is covalently attached to the polymer.5. An implantable medical device according to or claim 4 , wherein the polymer is a cationic polymer.6. An implantable medical device according to claim 5 , wherein the first coating layer comprises one or more coating bilayers of cationic polymer and anionic polymer claim 5 , the innermost layer being a layer of cationic polymer and the outermost layer being the layer of cationic polymer to which the heparin moiety is covalently attached.7. An implantable medical device according to claim 3 , wherein the heparin moiety is covalently end-point attached to the polymer and wherein the end-point attached heparin moiety is connected through its reducing end.8. (canceled)9. (canceled)10. An implantable medical device according to claim 1 , wherein the or each organic additive is non-polymeric and hydrolytically stable.11. (canceled)12. An implantable medical device according to claim 1 , wherein at least a proportion of the second particulate coating layer comprising paclitaxel and at least one organic additive melts as a single phase at a lower temperature than the ...

Drug Composition and Coating

According to the invention there is provided inter alia a medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent, when formulated in the coating layer, is stable to sterilization.

Drug Composition and Coating

According to the invention there is provided inter alia a medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent, when formulated in the coating layer, is stable to sterilization.

DRUG COMPOSITION AND COATING

According to the invention there is provided inter alia a medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent, when formulated in the coating layer, is stable to sterilization. 1. A medical device for delivering a therapeutic agent to a tissue , the device having a solid surfactant-free particulate coating layer applied to a surface of the device , the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent , when formulated in the coating layer , is stable to sterilization.2. A medical device for delivering a therapeutic agent to a tissue , the device having a solid surfactant-free particulate coating layer applied to a surface of the device , the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein the particulate coating layer is formed by evaporation of a solution of the therapeutic agent and the at least one organic additive applied to the device to form a ...

DRUG COMPOSITION AND COATING

According to the invention there is provided inter alfa a medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent, when formulated in the coating layer, is stable to sterilization. 1. A medical device for delivering a therapeutic agent to a tissue , the device having a solid surfactant-free particulate coating layer applied to a surface of the device , the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent , when formulated in the coating layer , is stable to sterilization.2. A medical device according to wherein the particulate coating layer is formed by evaporation of a solution of the therapeutic agent and the at least one organic additive applied to the device to form a solid particulate composition.3. (canceled)4. A medical device according to wherein the solution of the therapeutic agent and the at least one organic additive is a solution in a solvent selected from water claim 2 , acetone and mixtures thereof.5. A medical device ...

PROCESS THAT CONTINUES TO MAKE IMINODIASETIC ACID (PHOSPHONOMETHYL)

Implantable medical device

According to the invention there is provided inter alia an implantable medical device with coatings comprising an immobilized heparin moiety and elutable paclitaxel and to methods for making such devices.

Method of preparing amino carboxylic acids

Drug composition and coating

According to the invention there is provided inter alia a medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent, when formulated in the coating layer, is stable to sterilization.

Method of preparing amino carboxylic acids, such as N-(phosphonomethyl)glycine, via a carboxymethylation step

Continuous process for the preparation of N-(phosphonomethyl) iminodiacetic acid

Pericardial anchoring system

Various aspects of the present disclosure are directed toward apparatuses, systems, and methods for cardiac device anchoring and more specifically to accessing and anchoring in the pericardial space.

implantable medical device

a invenção se refere, entre outros, a um dispositivo médico implantável com revestimentos que compreende uma porção química de heparina imobilizada e paclitaxel eluível e aos métodos para fabricar tais dispositivos. the invention relates, among others, to an implantable medical device with coatings comprising a chemical portion of immobilized heparin and elucible paclitaxel and methods of making such devices.

Heterocycles derived from quinoline, selective inhibitors of pik3 activity; and a pharmaceutical composition comprising one of the compounds, useful for the treatment of inflammatory diseases, autoimmune diseases, rheumatoid arthritis and psoriasis, among others.

Compuestos derivados de heterociclos con N como heteroátomos, inhibidores selectivos de actividad PI3K; composición farmacéutica; y método de tratamiento de cáncer. Compounds derived from heterocycles with N as heteroatoms, selective inhibitors of PI3K activity; pharmaceutical composition; and cancer treatment method.

Pericardial anchoring system

Various aspects of the present disclosure are directed toward apparatuses, systems, and methods for cardiac device anchoring and more specifically to accessing and anchoring in the pericardial space.

Pericardial anchoring system

Various aspects of the present disclosure are directed toward apparatuses, systems, and methods for cardiac device anchoring and more specifically to accessing and anchoring in the pericardial space.

Pericardial anchoring system

Various aspects of the present disclosure are directed toward apparatuses, systems, and methods for cardiac device anchoring and more specifically to accessing and anchoring in the pericardial space.

Drug composition and coating

According to the invention there is provided inter alia a medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent, when formulated in the coating layer, is stable to sterilization.

Mitral valve leaflet repair system

Various aspects of the present disclosure are directed toward apparatuses, systems, and methods for cardiac device anchoring and more specifically to accessing and anchoring in the pericardial space.

[UNK]

[UNK]

Implantable medical device having coatings

Wrench

Carbon dioxide assisted hydrolysis of aminophosphonates

The invention provides a process for preparing aminophosphonic acids comprising contacting an aminophosphonate ester with a base in the presence of a hydrolysis facilitator selected from the group consisting of CO2, CS2 and COS. In one embodiment, the aminophosphonate ester is first prepared by contacting an amine, trialkylphosphite, base and formaldehyde.

Carbon dioxide assisted hydrolysis of aminophosphonates

Carbon dioxide assisted hydrolysis of aminophosphonates

Hidrolisis aminofosfonat yang dibantu karbondioksida

Carbondioxidassisteret hydrolyse af aminophosphonater

Kohlendioxid-assistierte hydrolyse von aminophosphonaten

Hidrólise de aminofosfonatos auxiliada por dióxido de carbono

Patente de Invenção: <B>"HIDRóLISE DE AMINOFOSFONATOS AUXILIADA POR DIóXIDO DE CARBONO"<D>. A invenção fornece um processo para preparar ácidos aminofosfónicos compreendendo o contato de um éster aminofosfonato com uma base na presença de um facilitador de hidrólise selecionado do grupo constituído de CO~ 2~, CS~ 2~ e COS. Em uma forma de realização, o éster aminofosfonato é primeiramente preparado pelo contato de uma amina, trialquilfosfito, base e formaldeído.

Carbon dioxide assisted hydrolysis of aminophosphonates

The invention provides a process for preparing aminophosphonic acids comprising contacting an aminophosphonate ester with a base in the presence of a hydrolysis facilitator selected from the group consisting of CO2, CS2 and COS. In one embodiment, the aminophosphonate ester is first prepared by contacting an amine, trialkylphosphite, base and formaldehyde.

Carbon dioxide assisted hydrolysis of aminophosphonates

Kohlendioxid-assistierte hydrolyse von aminophosphonaten